RecentRCT

Efgartigimod versus IVIG in impending myasthenic crisis

Primary publication linked by DOI, 2026 · Single-center open-label randomized trial

Population: 38 AChR-positive impending-crisis patients
Intervention: Efgartigimod
Comparator: IVIG
Primary outcome: One-month remission and time to remission
Result: Remission 90.48% versus 94.12%; median time 8 versus 12 days; one progressed to crisis in each arm.

What the trial found

Remission 90.48% versus 94.12%; median time 8 versus 12 days; one progressed to crisis in each arm.

Clinical interpretation

Small single-center open-label trial does not prove equivalence or safety and does not establish a substitute for rescue in ventilated crisis.

Low certainty

Clinical Context & Relevant Topics (1)

Disease Reference

Myasthenia Gravis & Myasthenic Crisis

Dedicated ICU management of myasthenic crisis: respiratory mechanics, airway timing, IVIG/plasma exchange, trigger control, medication hazards, and extubation.

View Topic Context →